Author:
So Jessica M,Umeh Chukwuemeka,Noriega Steven,Stratton Erica,Aseri Mahendra,Gupta Rakesh C
Reference13 articles.
1. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial;Marconi VC;Lancet Respir Med,2021
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19;Zhang X;Int Immunopharmacol,2020
3. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19;Jorgensen SC;Pharmacotherapy,2020
4. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. [In Press];Que Y;Int Rev Immunol,2021
5. Kinase inhibitors. Janus kinase inhibitors and Bruton’s tyrosine kinase inhibitors. (2021). Accessed: November 7, 2021 : https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献